Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery

  • STATUS
    Recruiting
  • participants needed
    135
  • sponsor
    Korea University Anam Hospital
Send
Updated on 16 February 2024
See if I qualify
cancer
body mass index
adenocarcinoma
gastric cancer
gastric adenocarcinoma
type 2 diabetes
endoscopic biopsy
bariatric surgery
gastrectomy
roux-en-y
roux-en-y anastomosis
billroth ii
diabetes

Summary

This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.

Description

Billroth I, Billroth II, or Roux-en-Y procedure follows gastrectomy to reconstruct the gastrointestinal tract. Billroth I procedure restores the normal configuration of the gastrointestinal tract and Billroth II and Roux-en-Y procedure involve the creation of duodenal switch which is thought to be responsible for metabolic effects by altering enteric hormones. Accordingly, several retrospective studies reported that Billroth I reconstruction has less effect on diabetes compared to Billroth II and Roux-en-Y reconstruction. While little is known about different effects of Billroth II and Roux-en-Y procedure, a study retrospectively showed that Roux-en-Y procedure has significantly higher rate of T2DM remission than Billroth II procedure. We conduct a randomized controlled trial to control possible confounders arising from diverse metabolic effects of cancer and minimize differences in treatment regimen among patients.

Details
Condition NIDDM, Gastropathy, Gastric Cancer, Gastric Cancer
Age 20years - 100years
Treatment Long limb Roux-en-Y reconstruction after subtotal gastrectomy, Conventional Roux-en-Y reconstruction after subtotal gastrectomy, Billroth II reconstruction after subtotal gastrectomy
Clinical Study IdentifierNCT04284943
SponsorKorea University Anam Hospital
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Distal gastric adenocarcinoma diagnosed pathologically under preoperative endoscopic biopsy, and clinical stage I-II
Body mass index 25 kg/m2
Type 2 diabetes and HbA1c 7.0%

Exclusion Criteria

Prior gastrointestinal surgery including splenectomy, hepatobiliary and pancreatic surgery (except hemorrhoidectomy, herniorrhaphy, and appendectomy)
Abdominal, thoracic, pelvic and/or obstetric-gynecologic surgery within 3 months
Cardiovascular conditions including significant known CAD, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension. Subjects with CAD that have been successfully treated with CABG or PCI, and have no evidence of active ischemia are eligible
Kidney disease including renovascular hypertension, renal artery stenosis, or end-stage renal disease
Chronic liver disease including liver cirrhosis, alpha-1 antitrypsin deficiency
Gastrointestinal disorders including inflammatory bowel disease (Crohn's disease or ulcerative colitis) or any malabsorptive disorders
Psychiatric disorders including dementia, active psychosis, history of suicide attempts, alcohol or drug abuse within 12 months
Severe pulmonary disease defined as FEV1 <50% of predicted value
Anemia defined as hemoglobin less than 8 in females and 10 in males
Malignancy within 5 years (except squamous cell and basal cell cancer of the skin). Subjects diagnosed with early or stage I cancer than have been successfully treated are eligible per investigator discretion
Any condition or major illness that, in the investigator's judgement, places the subject at undue risk by participating in the study
Unable to understand the risks, realistic benefits and compliance requirements of each program
Use of investigational therapy or participation in any other clinical trial within 3 months
Geographic inaccessibility
Pregnancy
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer
body mass index
adenocarcinoma
gastric cancer
gastric adenocarcinoma
type 2 diabetes
endoscopic biopsy
bariatric surgery
gastrectomy
roux-en-y
roux-en-y anastomosis
billroth ii
diabetes

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.